Latest IPF Studies Also Support Esbriet for More Severe Lung Function Impairment

Latest IPF Studies Also Support Esbriet for More Severe Lung Function Impairment

Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF).

The results of the studies were recently presented at the American Thoracic Society International Conference (ATS 2017) May 19-24 in Washington, D.C.

According to the presentation titled “Effect of Pirfenidone on Breathlessness as Measured by the UCSD-SOBQ Score in Patients with Idiopathic Pulmonary Fibrosis (IPF) with Moderate Lung Function Impairment,” Esbriet can reduce breathlessness in IPF patients with moderate lung function impairment compared to the placebo.

The authors of the study collected data from a total of 1,247 IPF patients who participated in the Phase 3 ASCEND (NCT01366209) and CAPACITY (NCT00287729 and NCT00287716) clinical trials.

The team found that patients with moderate lung function impairment treated for 12 months with Esbriet had a UCSD-SOBQ (University of California at San Diego Shortness of Breath Questionnaire) score increase of 9.2 compared to 13.0 in the placebo group. The higher the score, the worse the shortness of breath felt by the patient.

The second study presented at ATS 2017 was titled “Effect of Pirfenidone on All-Cause Mortality (ACM) and Forced Vital Capacity (FVC) in Idiopathic Pulmonary Fibrosis (IPF) Patients with Low FVC and/or Low DLCO: Analysis of Pooled Data from ASCEND and CAPACITY.”

In this study, researchers assessed information from 170 IPF patients collected from the ASCEND and CAPACITY trials (90 treated with Esbriet and 80 in the placebo group).

The team found that 12 months of Esbriet therapy in patients with low carbon monoxide diffusion capacity and low forced vital capacity (FVC; a measure of lung function) reduced the patients’ risk of all-cause mortality by 72 percent compared to the placebo. These patients also showed a reduction in FVC annual rate decline of 1.9 times compared to placebo-treated patients.

Based on the results, researchers suggested that Esbriet can significantly reduce mortality and delay lung function decline in IPF patients with severe lung function impairment.

Taken together, the positive results of these two independent studies support treatment with Esbriet for IPF symptoms even in patients with more severely impaired lung function.

4 comments

  1. Gayla says:

    My husband started Esbriet but when he started taking the 2 tabs. three times a day he would become worse. He never made it to taking 3 tabs 3x daily. He passed away after 36 days in the hospital. He was diagnosed in April and passed away in July. I pray that you find a cure for this terrible disease.

    • Alice Melão says:

      I am sorry to hear about you husband. Many times what works for others does not work for us, and is that individuality that makes us humans it is also what allows diseases to keep winning many of the fights. But I believe science will prevail.

  2. Charles R Kinder says:

    I started taking Esbriet June 5 2015 in January 2017 My condition had gotten worse. Now the doctor said my pulmonary fibrosis has gotten so bad all they can do is keep me on Oxygen 24/7. He also said that I might have another 5 Years.

  3. James Bales says:

    The most promising drug for IPF treatment seems to be the small pox vacine. There was a bill in Congress that allowed fast tracting drug trials for fatal diseases such as IPF. I know that it worked in mice but it doesn’t mean it will work for us but I would be a volunteer for such trials. What do we have to lose? What is the status of such trials? Some of the stuff that the FDA approved already seems to be harmful for the liver and could be a faster way to die for many so why not try something that gives hope where there is little hope right now of a cure..

Leave a Comment

Your email address will not be published. Required fields are marked *